Mr. F received several different treatment regimens for MM. He required a cardioprotectant, dexrazoxane, to continue treatment with the VAD regimen. He received interferon, high-dose chemotherapy with tandem stem cell transplants, and newer agents used in the treatment of MM, such as thalidomide and topotecan. However, as illustrated by Mr. F's case study, MM remains an incurable disease despite advances in its treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1188/02.CJON.359-362 | DOI Listing |
Publication Analysis
Top Keywords
treatment
5
multiple myeloma
4
myeloma treatment
4
treatment received
4
received treatment
4
treatment regimens
4
regimens required
4
required cardioprotectant
4
cardioprotectant dexrazoxane
4
dexrazoxane continue
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!